Merck Raises 2026 Profit Outlook Following Strong Q3 Earnings and Revenue Beat

Merck & Co. reported third-quarter 2026 financial results on October 29, significantly exceeding analyst expectations for both revenue and earnings. The company generated $18.1 billion in revenue for the quarter, representing a 5% increase year-over-year and surpassing the consensus estimate of $17.3 billion. Adjusted earnings per share (EPS) reached $2.49, a 19.1% beat against the $2.09 anticipated by Wall Street.

Following the performance, Merck raised its full-year 2026 adjusted EPS guidance. The company now expects a range of $2.77 to $2.82 per share, up from its previous forecast of $2.66 to $2.76.

The quarterly earnings were achieved despite a $0.12 per share charge related to a global license agreement with SciBrunch. Additionally, Merck noted that the top-line results were bolstered by approximately $550 million in favorable purchase timing from customers.

serves as a strategic bridge for Merck ahead of the 2028 patent cliff for its original oncology formulation.

Strategic Shift Toward Subcutaneous Delivery

A central component of Merck’s current strategy is the rollout of Keytruda Qlex, a subcutaneous version of its multi-billion-dollar oncology treatment. The FDA approved Keytruda Qlex for subcutaneous injection on September 19, 2025, offering a delivery method that takes only a few minutes compared to the traditional 30-minute intravenous infusion.

This transition is viewed by analysts as a critical defensive bridge ahead of the 2028 patent cliff for the original intravenous formulation of Keytruda. By shifting patients to the subcutaneous format, Merck aims to retain market share and provide a more convenient administration option as generic competitors for the original formula eventually enter the market.

Growth in Cardiovascular and Vaccine Portfolios

Beyond its oncology mainstay, Merck is seeing substantial growth from its newer product launches, particularly in the cardiovascular space. Sales of Winrevair, a treatment for pulmonary arterial hypertension, rose 94% year-over-year to $694 million during the third quarter.

The company is also advancing several late-stage pipeline candidates to diversify its revenue streams. These include sac-TMT, a TROP2 antibody-drug conjugate, and an mRNA-based cancer vaccine (intismeran autogene).

In its third-quarter 2026 financial results, Merck detailed that adjusted figures showed growth.

Management indicated that the $550 million purchase timing benefit included approximately $200 million specifically related to Keytruda, which is expected to unwind in the fourth quarter of 2026. This adjustment suggests a potential balancing of sales figures in the final months of the year as customer inventory levels normalize.

The post Merck Raises 2026 Profit Outlook Following Strong Q3 Earnings and Revenue Beat appeared first on World Weekly News.